CRON vs. ACAD, MLTX, VCEL, XENE, MOR, SWTX, MRUS, DNLI, BHC, and ZLAB
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include ACADIA Pharmaceuticals (ACAD), MoonLake Immunotherapeutics (MLTX), Vericel (VCEL), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Merus (MRUS), Denali Therapeutics (DNLI), Bausch Health Companies (BHC), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.
Cronos Group vs.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
ACADIA Pharmaceuticals presently has a consensus target price of $25.25, indicating a potential upside of 43.71%. Cronos Group has a consensus target price of $3.00, indicating a potential upside of 50.75%. Given Cronos Group's higher probable upside, analysts clearly believe Cronos Group is more favorable than ACADIA Pharmaceuticals.
In the previous week, ACADIA Pharmaceuticals had 11 more articles in the media than Cronos Group. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 1 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.30 beat ACADIA Pharmaceuticals' score of 0.56 indicating that Cronos Group is being referred to more favorably in the news media.
ACADIA Pharmaceuticals has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals has a net margin of 13.83% compared to Cronos Group's net margin of -42.65%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Cronos Group's return on equity.
ACADIA Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ACADIA Pharmaceuticals received 429 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 73.14% of users gave ACADIA Pharmaceuticals an outperform vote while only 61.13% of users gave Cronos Group an outperform vote.
Summary
ACADIA Pharmaceuticals beats Cronos Group on 14 of the 18 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cronos Group Competitors List
Related Companies and Tools
This page (NASDAQ:CRON) was last updated on 1/21/2025 by MarketBeat.com Staff